Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
about
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell functionRecommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience.A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanomaA melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodesA randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineImmunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesEffect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trialDynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines.Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survivalTumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artCharacterization of intrinsically disordered prostate associated gene (PAGE5) at single residue resolution by NMR spectroscopyUse of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.Recent advances in cancer vaccines: an overview.Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvantDengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.Immunotherapy of cancer in 2012.Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumabTherapeutic prostate cancer vaccines: a review of the latest developmentsDiffering patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.Trial watch: Peptide vaccines in cancer therapyPI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancerPeptide-based vaccines for cancer: realizing their potential.Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.
P2860
Q24611404-E130642D-8438-4E49-B0E6-879A76770339Q26796314-2779929D-8AF2-4EAF-AF57-486662A5306FQ28246944-5C3249F9-BBEC-45C9-B95B-A4FD997F669BQ28744503-3DC63B5E-B450-48CE-8FE9-A8C8B699CB83Q30275159-B5171BDD-3304-43EC-8A0B-E9B81E898623Q30276126-18106E31-ECEC-4E8F-B2A6-1FD9B261A6EEQ30276128-515AC74D-2D19-490F-9137-50233DCD17DBQ30278070-78453B6C-49E0-4DCF-A5D4-06D7C86558F1Q30278652-78A945DB-A5C6-4EE0-8FDC-C638D0063C29Q30300873-A8F08381-3FE5-4839-8E1E-7DB19DDACB4FQ30411269-25C0A252-1C09-4EB8-82BD-32AFCC4722E1Q30411499-0F4715A9-ECCD-433E-84F1-2A0EDCC7F017Q30412094-BBE8DB10-4AB6-4B45-8166-B034FA964184Q30423165-698B3DDA-3F81-4800-BF55-31233F0A8758Q30425111-90E30122-DD5E-410B-8039-E0E4AD5E2752Q30425914-25572500-154C-4F1D-A1C5-C854713878A1Q30429708-F751E890-07BD-4A4B-A76E-AF1FF7FDE337Q30430002-1FDEAC9B-6F25-4AA4-BA00-795D63782D9CQ30432896-F4B29D9C-F2D9-49FB-809C-812C5A6D86FAQ30433911-67101A0F-69F8-45A9-8B91-B2365849A442Q30434151-B1DB75CE-6B78-424F-B708-10C5B1AD063BQ30434822-FCBD808A-59AB-4634-9D8B-BBB5E1224C89Q30436792-1D81E4C6-8C70-4524-B92A-57D07C10621FQ33396199-C9949C72-2CD1-4C7F-9AAF-AE71A55AD4FCQ33406769-313C9F22-53CF-4E80-83A4-8D6D3640B032Q33907628-3801D056-57F6-44B2-B1E1-40397BAA50F4Q34071587-39D8AF64-1D22-44E7-960D-E6BC4E6AE18DQ34138324-F9BDD937-04CA-4DD7-ACC8-A749A69070ACQ34882348-6F58B9D6-8254-4E5F-ABAB-EEBA07A05BE9Q35125382-CDA60DA5-D8ED-450B-A3FA-53ABB91F48A5Q35886539-D4428989-1EF3-4404-B7AB-4A88637AB618Q36185518-5883890C-9264-4E31-A6E5-6FDE5E865275Q36243536-1A4474B8-70DF-463E-B7BA-99FBB9F81D6EQ36286948-6470F63C-FA4C-45E6-8682-A63F2906BBF1Q36365743-A605CC1C-2758-4765-839F-DA7433413E36Q36443331-21472450-E524-44BB-A53D-2EEB68214384Q36476100-DE7F0F91-9E65-4DC3-A590-398239793524Q37206391-F5A22215-5124-4D5C-9CF0-8A37D8A1D115Q37340462-C3424981-50A0-406F-B506-4CB482F89B44Q37354177-C6F35746-B0DD-4B17-BF09-0C2FDFF1209F
P2860
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Immunologic and clinical outco ...... anoma in the adjuvant setting.
@ast
Immunologic and clinical outco ...... anoma in the adjuvant setting.
@en
type
label
Immunologic and clinical outco ...... anoma in the adjuvant setting.
@ast
Immunologic and clinical outco ...... anoma in the adjuvant setting.
@en
prefLabel
Immunologic and clinical outco ...... anoma in the adjuvant setting.
@ast
Immunologic and clinical outco ...... anoma in the adjuvant setting.
@en
P2093
P1476
Immunologic and clinical outco ...... anoma in the adjuvant setting.
@en
P2093
Cheryl Murphy
Galina V Yamshchikov
Gina R Petroni
James W Patterson
Mark E Smolkin
Naomi Johansen
Patrice K Rehm
Patrice Y Neese
Robyn Fink
Sarah Hibbitts
P304
P356
10.1158/1078-0432.CCR-07-0486
P407
P577
2007-11-01T00:00:00Z